MFDS Approves Qinlock, an Orphan Drug for Gastrointestinal Stromal Tumors
The Ministry of Food and Drug Safety said it approved Qinlock 50 mg tablets (ripretinib) on October 16 for the treatment of gastrointestinal stromal tumors.
Gastrointestinal stromal tumors are tumors that develop in the tissues forming the walls of the stomach or intestines.
Qinlock is used to treat adults with advanced gastrointestinal stromal tumors who have previously been treated with three or more kinase inhibitors, including imatinib. It is classified as an imported orphan drug.
Hot Picks Today
"If You Don't Apply, My KRW 1.7 Million Will Be Gone"... Unclaimed National Pension Refunds Vanish After 'This Deadline'
- "I order out of habit, then regret it when I check my wallet"... Gen Z caught in 'delivery guilt'
- "When I get Home from Work, This Is All I Do, and It's Making Me Stupid"... Short-Form Craze Sparks 'Electronic Drug' Debate in China
- "Live king crab costs 3,000 won per geun": Chinese travel agencies go all out to recruit tourists for 'this country'
- "Beef Is Too Expensive, Let's Eat Chicken"... Japan's Dining Habits Shift Amid High Prices and a Weak Yen
The Ministry of Food and Drug Safety said, "This medicine may offer a new treatment option by inhibiting tyrosine kinases involved in the growth of cancer cells."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
!["Please Take Them Off!" They Made It All the Way to the Bed... Then "80% of Fecal Bacteria" Struck [Deep Scroll]](https://cwcontent.asiae.co.kr/asiaresize/307/2026101610053063338_1792112730.png)
